18 results on '"Verma, Sadhna"'
Search Results
2. Imaging Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: Past, Present, and Future.
- Author
-
Kasson, Matthew, Ortman, Michael, Gaitonde, Krishnanath, Verma, Sadhna, and Sidana, Abhinav
- Published
- 2018
- Full Text
- View/download PDF
3. Multiparametric MRI: An Opportunity for Focal Therapy of Prostate Cancer.
- Author
-
Calio, Brian, Kasson, Matthew, Sugano, Doraneh, Ortman, Michael, Gaitonde, Krishnanath, Verma, Sadhna, and Sidana, Abhinav
- Published
- 2018
- Full Text
- View/download PDF
4. ACR Appropriateness Criteria Staging of Testicular Malignancy.
- Author
-
Yacoub, Joseph H., Oto, Aytekin, Allen, Brian C., Coakley, Fergus V., Friedman, Barak, Hartman, Matthew S., Hosseinzadeh, Keyanoosh, Porter, Christopher, Sahni, V. Anik, Sudakoff, Gary S., Verma, Sadhna, Wang, Carolyn L., Remer, Erick M., and Eberhardt, Steven C.
- Abstract
Testicular cancer represents only 1% of all malignancies occurring in men. However, it is the most frequent malignancy in men between the ages of 20 and 34 years, accounting for 10% to 14% of cancer incidence in that age group. In most instances, the diagnosis of testicular tumors is established with a carefully performed physical examination and scrotal ultrasonography. Tumor markers are useful for determining the presence of residual disease. Cross-sectional imaging studies (CT, MRI) are useful in determining the location of metastases. Chest radiography and CT are used to assess pulmonary disease. Fluorine-18-2-fluoro-2-deoxy-d-glucose (FDG) PET scans have slightly higher sensitivity than CT, but their role in staging testicular cancer has not been determined in a large study. FDG PET may play a role in the follow-up of higher stage seminoma after chemotherapy. Bone scans are useful in the absence of FDG PET scans and should be used when bone metastases are suspected. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (the RAND/UCLA Appropriateness Method and the Grading of Recommendations Assessment, Development, and Evaluation) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances in which evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Common Technical and Anatomical Pitfalls in the Evaluation of Multiparametric Prostate Magnetic Resonance Imaging.
- Author
-
Liu, Xiaozhou and Verma, Sadhna
- Published
- 2015
- Full Text
- View/download PDF
6. Acute Knee Dislocation: Review of an Elusive Entity.
- Author
-
Kapur, Sangita, Wissman, Robert D., Robertson, Michael, Verma, Sadhna, Kreeger, Michael C., and Oostveen, Robert J.
- Abstract
The knee consists of three articulations: the patellofemoral, the tibiofemoral, and the proximal tibiofibular joint. Any of these joints can dislocate. Dislocations are uncommon, tend to spontaneously reduce, and can be difficult to detect on clinical examination. There are, however, telltale imaging features and the radiologist may be the first to suggest the correct diagnosis. A timely diagnosis is important as some forms are associated with limb-threatening complications. Lateral patellofemoral dislocation, in the acute setting, is typically an injury of young athletes and usually spontaneously reduces at the time of trauma. In transient lateral dislocation, contusions may be seen in the inferomedial pole of the patella and the anterior lateral aspect of the nonarticular portion of the femur. The important magnetic resonance imaging findings include this characteristic contusion pattern and injury to the medial patellar soft-tissue restraints. These are frequently associated with osteochondral fractures, which may be an indication for surgery. Recurrent patellofemoral dislocations tend to be associated with abnormalities of bony and/or soft-tissue restraints. The important imaging considerations are the length of patellar tendon, the depth of trochlear groove, and the position of patella in relation to the trochlear groove. Tibiofemoral dislocations are rare and are usually associated with high-impact trauma. These are multi-ligamentous injuries, which most often involve both cruciate ligaments with either medial and/or lateral ligament tears. There is an associated risk of popliteal artery and peroneal nerve injury, even if reduced, at the time of presentation. Dislocations of the tibiofibular joint are also rare and are classified based on location of fibular head. The tibiofibular joint is lax in flexion, and thus, most dislocations tend to occur in the flexed knee position. Anterolateral dislocation is the most common, while posteromedial dislocation is frequently associated with peroneal nerve injury. The purpose of this article is to review the epidemiology of knee dislocations, important imaging findings, and the most common complications. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
7. ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.
- Author
-
Froemming, Adam T., Verma, Sadhna, Eberhardt, Steven C., Oto, Aytekin, Alexander, Lauren F., Allen, Brian C., Coakley, Fergus V., Davis, Brian J., Fulgham, Pat F., Hosseinzadeh, Keyanoosh, Porter, Christopher, Sahni, V. Anik, Schuster, David M., Showalter, Timothy N., Venkatesan, Aradhana M., Wang, Carolyn L., Remer, Erick M., and Expert Panel on Urologic Imaging:
- Abstract
Diagnosis and management of prostate cancer post treatment is a large and complex problem, and care of these patients requires multidisciplinary involvement of imaging, medical, and surgical specialties. Imaging capabilities for evaluation of men with recurrent prostate cancer are rapidly evolving, particularly with PET and MRI. At the same time, treatment options and capabilities are expanding and improving. These recommendations separate patients into three broad categories: (1) patients status post-radical prostatectomy, (2) clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments, and (3) metastatic prostate. This article is a review of the current literature regarding imaging in these settings and the resulting recommendations for imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.
- Author
-
Coakley, Fergus V., Oto, Aytekin, Alexander, Lauren F., Allen, Brian C., Davis, Brian J., Froemming, Adam T., Fulgham, Pat F., Hosseinzadeh, Keyanoosh, Porter, Christopher, Sahni, V. Anik, Schuster, David M., Showalter, Timothy N., Venkatesan, Aradhana M., Verma, Sadhna, Wang, Carolyn L., Remer, Erick M., Eberhardt, Steven C., and Expert Panel on Urologic Imaging:
- Abstract
Despite the frequent statement that "most men die with prostate cancer, not of it," the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. The primary goal during baseline evaluation of prostate cancer is disease characterization, that is, establishing disease presence, extent (local and distant), and aggressiveness. Prostate cancer is usually diagnosed after the finding of a suspicious serum prostate-specific antigen level or digital rectal examination. Tissue diagnosis may be obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy. The latter requires a preliminary multiparametric MRI, which has emerged as a powerful and relatively accurate tool for the local evaluation of prostate cancer over the last few decades. Bone scintigraphy and CT are primarily used to detect bone and nodal metastases in patients found to have intermediate- or high-risk disease at biopsy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. ACR Appropriateness Criteria® Hematospermia.
- Author
-
Hosseinzadeh, Keyanoosh, Oto, Aytekin, Allen, Brian C., Coakley, Fergus V., Friedman, Barak, Fulgham, Pat F., Hartman, Matthew S., Heller, Matthew T., Porter, Christopher, Sahni, V. Anik, Sudakoff, Gary S., Verma, Sadhna, Wang, Carolyn L., Yoo, Don C., Remer, Erick M., Eberhardt, Steven C., and Expert Panel on Urologic Imaging:
- Abstract
Most men with hematospermia or hemospermia (HS) are young (<40 years of age), presenting with transient or episodic HS without other signs or symptoms of disease. The condition is self-limiting in most cases and idiopathic in nature. When a cause can be identified, infections of the urogenital tract are the most common. Imaging does not play a role in this patient population. In older men (>40 years of age), clinical screening for prostate cancer is advised. Furthermore, when HS is persistent or has symptoms, causes include obstruction or stricture at the level of the verumontanum, calcifications or calculi in the prostate, ejaculatory ducts or seminal vesicles, and cysts arising within these structures. Noninvasive imaging, predominantly transrectal ultrasound (TRUS) and MRI, can be used in men of any age with persistent or refractory HS, or other associated symptoms or signs. TRUS is considered as the first-line imaging with MRI used when TRUS is inconclusive or negative. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology.
- Author
-
Jia, Jemianne Bautista, Houshyar, Roozbeh, Verma, Sadhna, Uchio, Edward, and Lall, Chandana
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *COMPUTED tomography , *TUMOR classification , *FOLLOW-up studies (Medicine) , *RADIOLOGISTS , *MAGNETIC resonance imaging - Abstract
Objectives: Multi-parametric prostate magnetic resonance imaging (MRI) is considered the current imaging standard for detection and staging of prostate cancer. The combination of anatomical and functional imaging provided in this exam significantly increases the accuracy of prostate cancer detection. Computed tomography (CT) imaging has so far been found to be lacking in this regard, however observations at our academic institution as well as evidence present in the literature support the proposition that CT could indeed be helpful in detecting prostate abnormalities that correspond to neoplasm. The purpose of this study was to prove that areas of focal mass-like enhancement on CT imaging directly correlate with prostate neoplasms as revealed on multi-parametric MRI and follow-up targeted biopsy.Materials and Methods: This was a single institution retrospective study with 27 male subjects. Inclusion criteria required subjects to have a multi-parametric MRI of the prostate between January 1, 2014 and June 1, 2015 and a pelvic venous phase contrast-enhanced CT study between January 1, 2000 and June 1, 2015. Two blinded Radiologists read subjects' CT scans for any abnormalities of the prostate. CT and multi-parametric MRI results were compared and were considered concordant if focal or mass like enhancement to a greater degree than the background parenchyma was detected in the same areas of the prostate on CT scan as areas of decreased T2 signal, perfusion abnormalities, and restricted diffusion on multi-parametric MRI.Results: CT results were directly compared to multi-parametric MRI findings and biopsy results. The overall agreement of MRI and CT is 85.19% (95% CI: 67.52-94.08%). The positive percent agreement is 78.95% (95% CI: 54.43-93.95%) and the negative percent agreement is 100.0% (95% CL: 63.06-100.0%). When CT results are directly compared to biopsy results, sensitivity and specificity of CT are 63.64% (95% CI: 30.79-89.07%) and 100.0% (95% CI: 47.82-100.0%). The positive predictive value (PPV) is 100.0% (95% CI: 59.04-100.0%) and the negative predictive value (NPV) is 55.56% (95% CI: 21.2-86.3%). When compared to MRI, CT has a lower sensitivity and a higher specificity, as well as a higher PPV and NPV. Logistic regression analysis did not show a significant relationship between concordance of MRI and CT and Gleason score, time between studies, age, and Prostate-specific antigen (PSA) level.Conclusion: Incidental focal areas of mass-like enhancement in the peripheral prostate detected on venous phase contrast-enhanced CT imaging may indeed correlate with prostate neoplasm and it would be prudent to suggest further work-up with PSA and perhaps multi-parametric MRI, especially in high-risk patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use.
- Author
-
Barentsz, Jelle O., Weinreb, Jeffrey C., Verma, Sadhna, Thoeny, Harriet C., Tempany, Clare M., Shtern, Faina, Padhani, Anwar R., Margolis, Daniel, Macura, Katarzyna J., Haider, Masoom A., Cornud, Francois, and Choyke, Peter L.
- Subjects
- *
PROSTATE , *DIAGNOSIS , *PROSTATE cancer , *MEDICAL protocols , *OVERTREATMENT of cancer , *SYSTEMATIC reviews , *MAGNETIC resonance imaging - Published
- 2016
- Full Text
- View/download PDF
12. App-Based Yoga of Immortals: A Novel, Easy-to-use Intervention in the Management of Urinary Incontinence.
- Author
-
Tunuguntla, Hari Siva Gurunadha Rao, Tunuguntla, Renuka, Kathuria, Himanshu, Sidana, Abhinav, Chaudhari, Nidhiben, Verma, Sadhna, and Shivanand, Ishan
- Subjects
- *
URINARY incontinence , *YOGA , *BREATHING exercises , *SOUND therapy , *ACTIVITIES of daily living - Abstract
Objective: To study the effectiveness Yoga of Immortals (YOI) intervention in participants with urinary incontinence (UI) of all types. YOI uniquely combines specific yogic postures, breathing exercises, sound therapy & meditation and is practiced by many for general well-being.Materials and Methods: In this App-based cohort study, a survey was sent to the YOI app subscribers. Those who identified with UI and consented were sent the ICIQ-UI- SF (for mean symptom score & severity of UI), and the ICIQ-LUTS-QOL (for impact of UI on QOL) Questionnaires at baseline, 4, and 8 weeks. Global impression of improvement was assessed by PGI-I scale.Results: 258/422 participants (18-74 years) were included and showed significant decrease in mean scores on the ICIQ-UI-SF (4.06 ± 0.24 at baseline; 2.90 ± 0.22 at 4-weeks [p ≤ 0.001] and 3.44 ± 0.23 at 8 weeks [p ≤ 0.001]) and ICIQ-LUTS-QOL (28.36± 0.74 at baseline; 24.46± 0.70 at 4-weeks [p ≤ 0.001] and 25.78± 0.70 at 8 weeks [p≤ 0.001]). Additionally, the 55-60 year subgroup also had significant decrease in mean scores on ICIQ-LUTS-QOL (25.06 ±1.20 at base line; 21.69 ± 1.07 at 4 weeks [p ≤ 0.01] and 22.28 ± 0.96 at 8 weeks [p ≤ 0.01]).Conclusion: YOI intervention resulted in significant improvement in mean scores on ICIQ-LUTS-QOL; ICIQ-UI-SF; frequency and severity of urinary leak; and daily life activity. Majority of the participants felt 'very much better' on PGI-scale. Being app- based, it has the added advantage of the ability to be used anytime and anywhere. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer.
- Author
-
Sidana, Abhinav, Tayebi, Shima, Blank, Fernando, Lama, Daniel J., Meyer, Meredith, Saeed, Yusef, Tobler, Juliana, Hsu, Wei-Wen, and Verma, Sadhna
- Subjects
- *
ENDORECTAL ultrasonography , *CRYOSURGERY , *PROSTATE cancer , *PROSTATE cancer patients , *MAGNETIC resonance , *MAGNETIC resonance imaging , *FAILURE (Psychology) , *PROSTATE-specific antigen - Abstract
• Innovative Prostate Cancer Treatment: MRI-US guided cryoablation as a primary treatment for intermediate-risk prostate cancer, offering a less invasive approach for localized disease management while minimizing harm to adjacent healthy tissue. • Safe option with Promising Functional Outcomes: MRI-US guided cryoablation offers a safe alternative for intermediate-risk prostate cancer, preserving potency and continence post-treatment with minimal morbidity. • Challenges in Predicting Pathological Failure: Despite encouraging results, the study underscores the difficulty in accurately predicting and detecting pathological failure after focal therapy, emphasizing the need for ongoing monitoring and research. Focal therapy (FT) is a form of ablative treatment offered to men with localized, organ-confined prostate cancer (CaP). Pelvic multiparametric magnetic resonance imaging (mpMRI) and mpMRI/transrectal ultrasound fusion (MRI-US) guidance enable the precise delivery of FT with limited ablation of adjacent benign tissue or vital genitourinary structures. This article presents our findings on using MRI-US to perform FT as a primary treatment for men with intermediate-risk CaP. Thirty-six men underwent MRI-US fusion-guided FT cryoablation at a single center from 2018 to 2023 as a primary treatment for intermediate-risk CaP. Following FT, quarterly prostate-specific antigen (PSA) testing and a 6 to 9 month mpMRI and combined MRI-US targeted and systematic biopsy were performed. Oncological outcomes were determined using several endpoints containing biochemical recurrence, imaging failure, and pathological failure. Functional outcomes were measured using reported erectile dysfunction/potency rates, urinary incontinence rates, and the American Urologic Association Symptom Score (AUA-SS) and Sexual Health Inventory for Men (SHIM) indices. Median follow-up was 29.1 months, most (75%) of whom had grade group 2 CaP. Out of the 36 men, 32 (88.9%) completed the combined MRI-targeted and systematic biopsy follow-up after treatment. The study had no major complications, but 12 (33.3%) patients experienced Clavien-Dindo grade II or lower complications. For oncological outcomes, 6 (16.7%) men had biochemical recurrence, 9 (25%) showed imaging failure, and 8 (22.2%) met the criteria for positive biopsy- out-of-field vs. in-field. 88.2% of previously potent patients remained potent postoperatively at 12 months. All patients were continent at 12 months. There were no statistically significant changes in the AUA-SS and SHIM scores postoperatively. MRI-US-guided cryoablation to target lesions in intermediate-risk CaP appears to be a safe treatment option, with functional outcomes indicating minimal short and intermediate-term morbidity and acceptable oncological outcomes. However, despite close monitoring and follow-up, there is still a limitation in accurately predicting/detecting pathological failure after FT. The long-term durability of FT for intermediate-risk, organ-confined CaP remains uncertain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Cowper's gland hyperplasia: A potential pitfall at MRI of the prostate.
- Author
-
Kamal, Omar, Foster, Bryan R., Turner, Kevin, Verma, Sadhna, Woo, Sungmin, Bathala, Tharakeswara K., and Coakley, Fergus V.
- Subjects
- *
BENIGN prostatic hyperplasia , *GLANDS , *MAGNETIC resonance imaging , *HYPERPLASIA , *METASTASIS , *PROSTATE - Abstract
MRI features are presented in a multicenter retrospective series of five patients with a unilateral masslike lesion seen in the genitourinary diaphragm at MRI performed for known or suspected prostate cancer. In all cases, the lesion appeared as an encapsulated 1.3 to 3.0 cm mass of heterogeneous low or intermediate T2 signal intensity in the genitourinary diaphragm, and targeted biopsy demonstrated benign Cowper's gland tissue. This entity is a potential imaging pitfall that could result in a diagnosis of an exophytic nodule of benign prostatic hyperplasia or local spread of prostate cancer. We present these cases to facilitate correct identification of Cowper's gland hyperplasia as an occasional finding at MRI of the prostate. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.
- Author
-
Turkbey, Baris, Rosenkrantz, Andrew B., Haider, Masoom A., Padhani, Anwar R., Villeirs, Geert, Macura, Katarzyna J., Tempany, Clare M., Choyke, Peter L., Cornud, Francois, Margolis, Daniel J., Thoeny, Harriet C., Verma, Sadhna, Barentsz, Jelle, and Weinreb, Jeffrey C.
- Subjects
- *
PROSTATE , *MAGNETIC resonance imaging - Abstract
The Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) was developed with a consensus-based process using a combination of published data, and expert observations and opinions. In the short time since its release, numerous studies have validated the value of PI-RADS v2 but, as expected, have also identified a number of ambiguities and limitations, some of which have been documented in the literature with potential solutions offered. To address these issues, the PI-RADS Steering Committee, again using a consensus-based process, has recommended several modifications to PI-RADS v2, maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category. This updated version, described in this article, is termed PI-RADS v2.1. It is anticipated that the adoption of these PI-RADS v2.1 modifications will improve inter-reader variability and simplify PI-RADS assessment of prostate magnetic resonance imaging even further. Research on the value and limitations on all components of PI-RADS v2.1 is strongly encouraged. The Prostate Imaging Reporting and Data System (PI-RADS) Committee, using a consensus-based process, has recommended several modifications to PI-RADS version 2 (v2), maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category. The updated version is termed PI-RADS v2.1. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Renal Collision and Composite Tumors: Imaging and Pathophysiology.
- Author
-
Lall, Chandana, Houshyar, Roozbeh, Landman, Jaime, Verma, Sadhna, Goyenechea, Martin, Bhargava, Puneet, Pulford, Christopher, Okhunov, Zhamshid, Siaghani, Parwiz J., and Menias, Christine
- Subjects
- *
GENITOURINARY organ cancer , *BIOPSY , *CANCER radiotherapy , *PATHOLOGICAL physiology , *SURGICAL excision , *DIFFERENTIAL diagnosis , *COMPUTED tomography , *KIDNEY tumors , *MAGNETIC resonance imaging , *MULTIPLE tumors , *RENAL cell carcinoma , *PAPILLARY carcinoma - Abstract
Objective: To illustrate the imaging appearances of a spectrum of renal collision and composite tumors. Occurrence of collision and composite tumors in the genitourinary tract is rare compared to the usual occurrence of synchronous tumors.Methods: Case studies were chosen that represent the different tumors. Analysis was made on both the imaging and the pathology if excision was performed.Results: Presence of 2 different cell types can lead to confusing imaging findings, and biopsy or excision is typically needed for final diagnosis. Some composite tumors have a characteristic appearance on imaging based on their pathologic features.Conclusion: Familiarity with imaging findings may help radiologists include these tumors in their differential diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
17. How does a prebiopsy mri approach for prostate cancer diagnosis affect prostatectomy upgrade rates?
- Author
-
Sussman, Jonathan, Haj-Hamed, Monzer, Talarek, Jeffrey, Verma, Sadhna, and Sidana, Abhinav
- Subjects
- *
PROSTATE cancer , *CANCER diagnosis , *PROSTATECTOMY , *RADICAL prostatectomy , *MAGNETIC resonance imaging , *ULTRASONIC imaging , *BIOPSY , *RETROSPECTIVE studies , *PROSTATE tumors - Abstract
Background: To compare the pathologic upgrade and downgrade rates after radical prostatectomy (RP) between patients diagnosed by prebiopsy prostate MRI followed by a combination of systematic and fusion biopsy (ComBx) versus patients undergoing systematic biopsy only (SBx).Methods: A retrospective review of men undergoing RP at our institution between Jan 2014 and Mar 2020 was performed. These patients were separated into two independent cohorts based on two approaches: Patients receiving prebiopsy prostate MRI during initial evaluation and those who did not receive MRI. Patients with positive MRI findings underwent subsequent ComBx to confirm diagnosis while those without MRI underwent standard trans-rectal ultrasound (TRUS) guided systematic 12-core biopsy (SBx). Primary outcomes were rates of pathological upgrade (prostatectomy grade higher than grade determined at time of biopsy) and downgrade (prostatectomy grade lower than biopsy grade).Results: A total of 213 patients undergoing radical prostatectomy, 91 diagnosed via a prebiopsy MRI and ComBx approach and 122 diagnosed by a traditional SBx approach, were included in the study. There was no significant difference between age, PSA, or positive family history between the two cohorts. Of the 91 patients who received prebiopsy MRI, 88 patients were determined to have a PIRADS 4 or 5 lesion. Patients who received MRI and subsequent ComBx had a lower rate of any pathological upgrade after RP (9.89% vs. 22.13%, P = 0.018) without a significant difference in pathologic downgrade rate (28.57% vs. 18.85%, P = 0.095). On multivariable logistic regression, receiving prebiopsy MRI during initial evaluation was the single negative independent predictor of pathologic upgrade (OR = 0.23, P = 0.017). A prebiopsy MRI approach was also the single predictor of pathologic downgrade (OR = 3.13, P = 0.041).Conclusions: Patients receiving prebiopsy MRI during prostate cancer evaluation were less likely to have their PCa upgraded. Furthermore, although diagnosis via MRI and subsequent ComBx was associated with an increased rate of downgrades after RP, relatively few resulted in a downgrade from clinically significant to clinically insignificant cancer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16–40.
- Author
-
Barentsz, Jelle O., Choyke, Peter L., Cornud, Francois, Haider, Masoom A., Macura, Katarzyna J., Margolis, Daniel, Shtern, Faina, Padhani, Anwar R., Tempany, Clare M., Thoeny, Harriet C., Verma, Sadhna, and Weinreb, Jeffrey C.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PROSTATE , *PROSTATE biopsy , *MAGNETIC resonance imaging - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.